Quifenadine
Not to be confused with quinidine.
![]() | |
| Clinical data | |
|---|---|
| Trade names | Fencarol |
| Routes of administration | Oral (tablets), IM injection |
| ATC code | R06AX31 (WHO) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 45% (Tmax = 1 hour)[1] |
| Metabolism | Liver |
| Identifiers | |
| |
| Synonyms | 3-Quinuclidinyldiphenylmethanol |
| CAS Number | 10447-38-8 |
| PubChem (CID) | 65600 |
| ChemSpider | 59041 |
| UNII |
W9A18RJ49B |
| KEGG | D10230 |
| ChEMBL | CHEMBL1187694 |
| Chemical and physical data | |
| Formula | C20H23NO |
| Molar mass | 293.40 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Quifenadine (Russian: хифенадин, trade name: Phencarol, Фенкарол) is an 2nd generation antihistamine drug, marketed mainly in post-Soviet countries.[2][3] Chemically, it is a quinuclidine derivative.
Indications
- Allergic rhinitis
- Acute and chronic urticaria
- Angioedema
- Dermatitis
- Atopic dermatitis
- Pruritus[1]
References
- 1 2 "Fencarol (quifenadine) Tablets, for Oral Use. Full Prescribing Information". State Register of Medicines (in Russian). Retrieved 4 January 2016.
- ↑ "Quifenadine". Drugs.com. Retrieved 28 January 2014.
- ↑ Makarov, L.; Balykova, L.; Soldatova, O.; Komolyatova, V.; Serebruany, V. (2010). "The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: A randomized controlled pilot trial". American journal of therapeutics. 17 (4): 396–401. doi:10.1097/MJT.0b013e3181a86987. PMID 19487925.
This article is issued from Wikipedia - version of the 11/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
